CART84 therapy for AML and T-ALL leukemia
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new treatment called CART84 (GYA01) for patients with acute myeloid leukemia (AML) or T-cell acute lymphoblastic leukemia (T-ALL) that has come back or not responded to standard treatments. CART84 uses specially engineered immune cells to target and destroy leukemia cells that have a protein called CD84 on their surface.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have AML or T-ALL with at least 5% leukemia cells in your bone marrow or blood, and no other approved treatment options available.
- Your leukemia cells must have the CD84 protein (confirmed by a lab test).
- You must be able to perform daily activities with little or no help (ECOG score 0 or 1).
- Your heart, lungs, kidneys, and liver must be working well enough (you will be tested).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment using your own immune cells, modified to target a protein called CD84 on leukemia cells. It is for adults with acute myeloid leukemia that has come back or not responded to standard treatments.
This trial tests whether a new immune therapy (CAR-T cells) can treat certain types of blood cancers that have come back or not responded to standard treatments. It aims to help people with aggressive B-cell lymphoma or acute lymphoblastic leukemia (ALL) that hasn't been controlled by other therapies.
This trial tests a new CAR-T cell therapy for children, teens, and young adults with acute lymphoblastic leukemia that has not responded to standard treatment. The goal is to see if the therapy can put the leukemia into remission so the patient may then have a stem cell transplant.
This trial tests a type of immunotherapy called CAR-T cells that are made from your own blood cells and are designed to find and destroy leukemia cells. It is for patients whose leukemia has come back or hasn't gone away after other treatments.
This trial tests a new CAR T-cell therapy called MB-CART2219.1 in people with certain types of blood cancer (like lymphoma or leukemia) that have come back or not responded to other treatments. CAR T-cells are your own immune cells that are modified to better find and kill cancer cells.
This trial tests a new type of cell therapy (U69-CART cells) that targets a specific protein (CCR9) found on leukemia cells in people whose T-cell acute lymphoblastic leukemia or lymphoma has come back or hasn't responded to standard treatments. The goal is to see if this therapy can help control the disease.
Hear when a new Acute Myeloblastic Leukaemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.